Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses Selinexor its mechanism of action and as it restores the activity of tumor-suppressant proteins at the 2017 American Society of Hematology.
Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses Selinexor its mechanism of action and as it restores the activity of tumor-suppressant proteins at the 2017 American Society of Hematology.